麗珠醫藥(01513.HK)：董事會批准麗珠生物股權轉讓與增資事項
格隆匯 1 月 11日丨麗珠醫藥(01513.HK)公佈，2021年1月8日，臨時股東大會已批准重組框架協議及其項下擬進行的交易，並授權董事會訂立進一步協議，以使重組框架協議項下擬進行的交易生效。根據該授權，董事會於2021年1月11日批准《關於珠海市麗珠生物醫藥科技有限公司股權轉讓與增資的議案》，以實現重組框架協議項下麗珠生物擬進行的股權轉讓與增資。
為實現此次股權轉讓，於2021年1月11日，公司與健康元分別與麗珠香港簽訂了股權轉讓協議。據此，公司及健康元同意分別以人民幣2431.629萬元(對應認繳出資額人民幣1.275億元)及人民幣2336.271萬元(對應認繳出資額人民幣1.225億元)的價格向麗珠香港收購麗珠生物51%及49%的股權。公司及健康元將承接未實繳出資部分的出資義務。此次股權轉讓工商變更登記完成後3個月內，公司及健康元將股權轉讓協議約定的全部股權轉讓款支付至麗珠香港指定的銀行帳户，雙方另行協商一致在其他時間支付的除外。
次股權轉讓完成後，麗珠生物將分別由公司及健康元持有51%及49%。
為實現此次增資，於2021年1月11日，公司、健康元、麗生聚源與麗珠生物簽訂了增資協議。據此，麗珠生物的註冊資本由人民幣25000萬元增加至人民幣66666.6667萬元，增加部分由公司、健康元及麗生聚源按照持股比例以每人民幣1元註冊資本對應每人民幣1元認購，其中：(1)公司認繳人民幣17850萬元的出資額；(2)健康元認繳人民幣17150萬元的出資額；及(3)麗生聚源認繳人民幣6666.6667萬元的出資額。
此次增資工商變更登記完成後3個月內，公司與健康元將增資協議約定的全部認繳出資額支付至麗珠生物指定的銀行帳户；麗生聚源根據麗珠生物制定的新子公司股份激勵計劃規定時間另行支付，各方另行協商一致在其他時間支付的除外。
此次增資完成後，麗珠生物將分別由公司、健康元及麗生聚源持有45.90%、44.10%及10.00%。
重組實施還需根據各方後續簽署的相關文件逐步落實和推進，受市場環境變化、監管環境變化或不可抗力等因素影響，後續實施過程中存在一定的不確定性，完成情況取決於工商變更登記、銀行付匯程序、境外減資程序等完成時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
